Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koenig - President, CEO & Director LeAnne Bloedon Conference Call Participants Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone.
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. ( ESPR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financial Officer Lisa Schafer Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and thank you for standing by.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Lisa Schafer - Corporate Participant Sheldon L. Koenig - President, CEO & Director Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Joseph Pantginis - H.C.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.05 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
